Bioventus Class A Inc (BVS) valuation
Bioventus Class A P/E ratio history
Bioventus Class A trades at 17.3 times its earnings over the last twelve months and 15.7 times the earnings analysts expect over the next twelve.
| Fiscal year ended | Price | EPS | P/E | Forward P/E |
|---|---|---|---|---|
| Dec 31, 2025 | $7.44 | $0.33 | 22.6 | 11.1 |
| Dec 31, 2024 | $10.50 | -$0.56 | n/m | — |
| Dec 31, 2023 | $5.27 | -$2.49 | n/m | — |
| Dec 31, 2022 | $2.61 | -$2.59 | n/m | — |
| Dec 31, 2021 | $14.49 | — | n/m | 14.5 |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Bioventus Class A valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| Bioventus Class ABVS | $1.11B | 17.3 | 15.7 | 1.9 |
| Omada HealthOMDA | $1.11B | 17.5 | 37.8 | 3.6 |
| Castle BiosciencesCSTL | $1.13B | — | — | 3.2 |
| ArtivionAORT | $1.10B | — | 39.4 | 2.3 |
| Lumexa ImagingLMRI | $1.10B | — | — | — |
| Procept BioroboticsPRCT | $1.09B | — | — | 3.2 |
| Lb PharmaceuticalsLBRX | $1.14B | 1.7 | — | — |
| Alphatec HoldngsATEC | $1.09B | — | 13.3 | 1.3 |
| MannkindMNKD | $1.08B | — | 43.8 | 2.8 |
| Peer median | 9.6 | 38.6 | 3.0 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: BVS financials · BVS returns
No forecast, no recommendation. This page describes Bioventus Class A Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.